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ABSTRACT 
 
The evolution of the carcinogenic process requires the knowledge of physiology and 
metabolism of cancer stem cells (CSCs), which seems be crucial for the development of 
novel effective therapies. In order to understand this process, mitochondria are 
unequivocally a target for cancer therapy and crucial in cell death. Given the relevance 
of mitochondrial metabolism for stemness maintenance, mitochondrial control of 
apoptosis and the importance of cardiolipin (CL) for mitochondrial metabolism, we 
proposed the study CL alterations during CSCs differentiation, so that CSCs resistance 
to therapies can be better understood. Our results indicate that, although the total 
content of CL did not significantly changed, CL remodeling, possible mediated by 
increased of taffazin and CLS amount, may lead to a metabolic transformation towards 
the typical oxidative metabolism that occurs during the differentiation of P19 CSCs. 
Differences in CL molecular species were observed with incorporation of oleic acid into 
CL from P19 CSCs. Moreover, the differentiation of P19 CSCs increased the 
peroxidation of CL. In a secondary objective of this work was to verify whether 
melatonin could affect P19 CSC proliferation. The results indicated that melatonin was 
only effective in reducing the proliferation of P19 cells with higher oxidative 
metabolism and was able to prevent CL peroxidation. Likewise, in cells with active 
oxidative metabolism, melatonin triggered a type of mitochondrial cell death which was 
mediated by the apoptosis-inducing factor (AIF). We conclude that the metabolic 
remodeling during P19 CSCs differentiation probably also involves alteration in CL 
metabolism that probably contributes in converting differentiated cells more susceptible 
to mitochondrial-targeted antitumor agents.  
 
 
Keywords: Cardiolipin, remodeling, cancer stem cells, melatonin 
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SUMÁRIO 
 
A evolução do processo carcinogénico requer o conhecimento da fisiologia e 
metabolismo das células estaminais de cancro (CEC) crucial para o desenvolvimento de 
novas e eficazes terapias. Uma vez reconhecido o seu importante papel no processo de 
morte celular, as mitocôndrias são inequivocamente um alvo promissor na terapia anti-
tumoral. Dada a relevância do metabolismo mitocondrial na manutenção da 
pluripotência das células estaminais e a importância da cardiolipina (CL), no 
metabolismo mitocondrial, propusemos o estudo das alterações na CL durante a 
diferenciação de CEC de forma a entender a sua resistência a terapias. Os nossos 
resultados indicam que, embora o conteúdo total de CL não se tenha alterado de forma 
significativa, a remodelação da CL acompanhou a transformação metabólica em função 
do típico metabolismo mais oxidativo que ocorre durante a diferenciação de P19 CEC. 
Diferenças nas espécies moleculares CL foram observadas com a incorporação de ácido 
oleico na CL nas P19 CEC. Adicionalmente foi observado um aumento na peroxidação 
da CL durante a diferenciação das CEC. Um segundo objetivo deste trabalho foi 
verificar se a melatonina poderia afetar a proliferação das CEC P19. Os resultados 
indicaram que a melatonina, induziu uma redução na proliferação de células com maior 
metabolismo oxidativo e foi capaz de prevenir a peroxidação de CL em células 
diferenciadas. Do mesmo modo, em células com o metabolismo oxidativo ativo, a 
melatonina provocou um tipo de morte celular mitocondrial mediada por um fator 
indutor de apoptose. Concluímos assim que a remodelação metabólica durante a 
diferenciação de CEC P19, pode envolver alterações no metabolismo da CL que 
possivelmente contribuem para aumentar a suscetibilidade das células diferenciadas a 
agentes anti-tumorais direcionadas à mitocôndria.  
 
 
Palavras-chave: Cardiolipina, remodelação, células estaminais de cancro, melatonina 
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1.1 - Stem Cells and Cancer Stem Cells  
 
Stem cells are defined as undifferentiated cells with self-renewal potential that are able 
to differentiate into a large number of diverse mature progeny. Amongst the various 
categories of stem cells, embryonic stem cells are pluripotent and are able to 
differentiate into any cell type due to the influence of microenvironmental and some 
other factors such as microRNAs expression
1
, making them a very promising 
foundation for stem cell-based therapeutics
2
. Stem cells can divide asymmetrically 
producing two daughter cells – one being a new stem cell and the second a progenitor 
cell, which has the ability for differentiation and proliferation, but without self-renewal 
potential. Stem cells can also divide symmetrically resulting in two cells equal to itself 
with essentially the same development and replication potential, keeping a constant pool 
of stem cells. 
Similarly to organs, tumors are composed of a mixture of cells at varying states 
of differentiation and arise from cells with the ability to proliferate indefinitely and 
differentiate into multiple lineages of cells
3,4
. In healthy tissues, stem cells are 
responsible for organ development, suggesting that tumors also have a subset of cells 
with stem-like characteristics known as cancer stem cells
3
. Over the past decade, 
support for the existence of cancer stem cells has grown, suggesting that cancer stem 
cells are a driving force in tumorigenesis.  
Cancer development and maintenance can be explained by two different models: 
the cancer stem cell model and the clonal evolution model
5
 (Figure 1). The cancer stem 
cells model presumes that tumor progression is a result of the metastatic spread of these 
cells tumorigenic, which are relatively more slow-growing or quiescent, and then 
relatively more resistance to therapy
4
. On the other hand, the clonal evolution model or 
the stochastic model proposes that any tumor cell has the potential to be involved in 
tumor progression and consequentially becoming invasive and also resistant to 
therapies
5
.  
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Figure 1.1 - Two general models to explain heterogeneity in solid cancer cells. a. Stochastic 
clonal evolution model: cancer cells of many different phenotypes have the potential to 
proliferate extensively, but any single cell would have a low probability of exhibiting this 
potential in an assay of clonogenicity or tumorigenicity. b, Cancer stem cell hierarchy model: 
most cancer cells have limited proliferative potential and only a subset of cancer cells 
consistently proliferate extensively in clonogenic assays and can form new tumors on 
transplantation. (Taken from Reya et al. 
3
 with permission – Appendix 1)  
 
Cancer stem cells, described above, can derive from adult stem cells in various 
developed tissues, but also from early embryonic stem cells. This category of cancer 
stem cells are known as embryonal carcinomas (EC). EC cells are the stem cell 
subpopulation of a category of malignant germ cell tumors known as teratocarcinomas
6
. 
In fact, recently it was proposed that P19 EC cells can provide an important cell model 
to study the differentiation and chemoresistance in cancer stem cells
3
. P19 cells are 
derived from a teratocarcinoma formed by transplantation of a 7.5 day embryo into the 
testis
7
. The development of P19 EC cell lines was a result from the establishment of cell 
lines using female embryos which were heterozygous for X-linked P19 EC alleles
7
. For 
this purpose, 7.5-day-old embryos derived from crossing a C3H/He female with males 
carrying an X-chromosome derived from a feral mouse bearing a number of variant 
alleles, were transplanted into the testis of a C3H/He mouse receptor. Undifferentiated 
P19 EC cells derived from the primary tumor have a euploid karyotype and grow 
rapidly in culture without the need for feeder cells (Figure 1.2 A,B,C).  
An efficient differentiation of P19 EC cells depends on whether the cells are 
cultured is at a high density
8
 or if they form aggregates
9
 (Figure 1.4 D,E,F). The 
compounds most effective in inducing differentiation of P19 cells are retinoic acid 
(RA)
10
 and dimethyl sulfoxide (DMSO)
8
.  Both compounds are not demonstrably toxic 
5 
 
to P19 cells at the doses effective in inducing differentiation, indicating that their effect 
is true induction and not selection of pre-existent differentiated cells
11,12
. The precise 
effect induced by RA seems to be variable depending on the particular cell line used and 
on whether or not cells are exposed to the agent as aggregates or in monolayer. At the 
dose of RA normally used (3x10
-7 
M), neurons are the first and most abundant cell type 
resulting from P19 cells growing as spheroids 
10
. Also, oligodendrocytes can be 
originated from RA-treated cells although this differentiation has only been observed in 
P19 cells grafted into the brains of neonatal rats
13
. At least three days after RA 
treatment, the first markers of differentiated neurons appear, confirming that RA has an 
important role in signaling pathways that culminates in cellular differentiation
14
.   
 
The site of RA action appears to be a group of nuclear retinoic acid receptors 
(RARs) that are known to be ligand-dependent transcription factors
15
. Binding of RA to 
RARs alters the conformation of the RARs, which affects the binding of other proteins 
that either induce or repress transcriptional activity of nearby genes (including Hox 
genes and several other target genes)
16
. Retinoic acid receptors mediate the transcription 
of different sets of genes controlling differentiation of a variety of cell types. Other 
agent that induces P19 EC cells differentiation into all three germ layers is DMSO. 
About 0.5–1% DMSO efficiently induces P19 cell aggregates to develop into a wide 
variety of mesodermal and endodermal cell types
14,17
 including cardiac and skeletal 
muscle, epithelium and other  uncharacterized cells. Treatment P19 EC cells or other 
cells types with DMSO, leads to an increase in intracellular calcium released from 
intracellular stores, which could trigger crucial events for cardiac muscle 
differentiation
18
. However, the molecular events that occur during aggregation and that 
are necessary for cardiac differentiation are not yet fully understood.  
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Figure 1.2 - Characteristics of P19 stem cells (P19SCs) versus differentiated cells 
(P19dCs).  Imaged by epifluorescence microscopy with Hoechst labeling for nuclear staining 
and electron microscopy. Detailed photographs of nuclei (A, B) and nucleolus (C) present in 
P19SCs. E and F represent nuclei and visible heterochromatin in P19dCs respectively. Bars = 
15 μm (A, B, D, E) and 3 μm (C, F). (Taken from I, Vega-Naredo et. al. 8 with permission – 
Appendix 2) 
7 
 
The critical problem in the development of anti-cancer therapies is effectively 
the presence of different groups of cells in tumor bulb. For this reason most of the usual 
therapies anti-cancer has their action failed in some tumors.  In the conventional view of 
drug resistance, one or several cells in the tumor population acquire genetic changes that 
confer drug resistance
19
. These cells have a selective advantage that allows them to 
overtake the population of tumor cells following cancer chemotherapy. After selection 
for resistance to a single drug, cells may also show cross-resistance to other structurally 
and mechanistically unrelated drugs — a phenomenon that is known as multidrug 
resistance
20
, which explain why treatment regimens that combine multiple agents with 
different targets are not more effective
19
. Cancer stem cells resistance to standard 
chemotherapeutics has been reported in human leukemia
21
 malignant melanoma
22
, 
brain
23
, and breast
24
 cancer. Furthermore cancer stem cells resistance to radiotherapy 
has also been reported in some brain
25
 and breast
26 
cancers. 
Several hypotheses have been proposed to account for the phenomenon of drug 
resistance. The hypotheses include the increased expression of anti-apoptotic BCL-2 
family members, alteration of drug transport across the plasma membrane, as 
consequence of the ABC-transporter over-expression, activation of DNA repair 
mechanisms, and alteration in target molecules
19
.
   
The main mechanism underlying the 
ability of CSCs to resist chemotherapy is the inhibition of apoptosis. Apoptosis is a 
regulated process by which a cell undergoes programmed death, resulting in 
fragmentation of the cell into membrane-bound particles that eventually are 
phagocytosed by specialized cells. A key signaling phenomenon responsible for 
triggering the cascade of events that precedes cell death is the release of cytochrome c 
from the inter-membrane space. Cytochrome c activates proteins responsible for 
executing the apoptotic program-caspases cascade. The mitochondrial apoptotic 
pathway is in turn regulated by members of the Bcl-2 family
27
 including pro-apoptotic 
p53 transcriptional targets like Bax, Bak, Noxa, and PUMA
28
 and anti-apoptotic 
members such as Bcl-2 and Bcl-xl
28
. Thus, cancer cells with Bax depletion are resistant 
to mitochondria-mediated apoptosis
29
 and overexpression of exogenous Bcl-xL or Bcl-2 
suppresses apoptosis
30
. On the other hand, downregulation of Bcl-xL or Bcl-2 can 
enhance the apoptotic response to DNA damage, but in a p53- and Bax-dependent 
manner. Another significant mechanism of resistance against a variety of anti-cancer 
8 
 
drugs is through the action of a group of membrane proteins which excludes cytotoxic 
molecules, keeping intracellular drug concentration below a cell-killing threshold.  The 
first of these carriers to be identified and characterized was P-glycoprotein (also known 
as MDR1), which is a member of the superfamily of ABC transporters (ATP-binding 
cassette), that is encoded by the ABCB1 gene
31
. Tumors with MDR protein 
overexpression
32,33,34 
frequently show intrinsic resistance
35
. However, the action of 
some therapies can be altered by the modification of its target and then their therapeutic 
potential influenced
36
. This way, the cell has no longer a known useful target to block.  
 
Due to the CSCs resistance to chemotherapy, novel therapeutic approaches have 
been designed with the aim of killing CSCs and altering the microenvironment 
supporting these cells. Some these approaches include cellular markers as CD133 (also 
known as Prominin1)
37
, CD44, CD24, epithelial cell adhesion molecule (Ep- CAM), 
THY1 and ATP-binding cassette B5 (ABCB5)
38
. Some therapies using CD133 and/or 
EpCAM and ABCC5 antibodies to prevent tumor progression and metastasis are being 
tested in different clinical trials
39,40,41
 .  
 
 
 
1.2 – Mitochondria in cancer stem cells 
 
Mitochondria play a relevant role in the cellular metabolism and for coordinating 
extrinsic and intrinsic signals which direct cell growth, proliferation differentiation, and 
death
42,43
. Dysfunction in the mitochondrial machinery has a major role in aging and 
apoptosis and contributes for many diseases including cancer. There are several 
processes associated to mitochondria that allow distinguishing cancer cells from normal 
healthy cells such as an increase in membrane potential associated to a decrease of 
mitochondrial ATP production and increased glycolytic ATP production
44
. In fact, the 
fast-growing of tumor cells are characterized by a high glycolytic activity, even in the 
presence of saturating oxygen, the so-called Warburg effect
45
. Warburg proposed that 
neoplastic cells undergo a metabolic shift from aerobic respiration to aerobic glycolysis, 
involving lactic acid fermentation, which would occur even at normal oxygen tensions.  
Moreover, he also proposed that cancer cells rely on less efficient aerobic glycolysis to 
achieve their energy requirements due to defects in the oxidative phosphorylation 
metabolic pathway
45
. In fact, despite the presence of functionally competent 
9 
 
mitochondria, the allosteric modulation of glycolytic enzymes in tumor cells prevents 
mitochondrial ATP production
46
 whereby non-tumor cells normally rely on aerobic 
respiration which makes use of both cytosolic and mitochondrial processes to generate 
energy. Contrarily, the glycolytic profile of the CSCs seems to be  consequence of 
reduced mitochondrial activity, yet have low rates of O2 consumption that accurately 
reflect their lack of reliance on OXPHOS for energy production. 
Mitochondria have been shown to change in number, structure and physiological 
function with cell differentiation
47
. Studies investigating mitochondrial changes in 
neuronal differentiation of P19 EC cells have reported increases in mitochondrial mass 
with differentiation in both existing studies. Conflicting results were reported for 
mtDNA copy number
48
 with unchanged mitochondrial mass and mtDNA during RA-
induced P19 EC cell differentiation
49
. Previous results from our laboratory showed that 
in comparison with their differentiated counterparts, pluripotency of P19SCs was 
correlated with a strong glycolytic profile, decreased mitochondrial biogenesis and 
complexity. Indeed, low-polarized and inactive mitochondria with a closed permeability 
transition pore were observed in P19SCs (Figure 1.3). Furthermore when P19SCs were 
differentiated with RA, they lost pluripotency while retaining their immortality and 
some stem-like properties. The decreased mitochondrial capacity observed in P19SCs 
was related to increased resistance against dichloroacetate
49
. Dichloroacetate (DCA), a 
mitochondria-targeting small molecule, has been shown to reverse the abnormal 
metabolism of cancer cells by shifting it from glycolysis to glucose oxidation through 
inhibition of pyruvate dehydrogenase kinase (PDK)
50
. DCA indirectly stimulates 
conversion of pyruvate to acetyl-CoA and up-regulates mitochondrial metabolism
51
. 
Dichloroacetate is also reported to reduce proliferation, increase apoptosis and to 
suppress tumor growth by normalizing mitochondrial function
51,52
. Thus, stimulation of 
mitochondrial function by growing P19SCs in glutamine/pyruvate-containing medium 
decreased their glycolytic phenotype, inducing loss of pluripotent potential, 
compromising differentiation and became P19SCs sensitive to DCA. 
10 
 
Because of the central role of this type of stem cells in teratocarcinoma 
development, those findings highlight the importance of mitochondrial metabolism in 
stemness, proliferation, differentiation and chemoresistance. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 – Alterations in mitochondrial morphology during P19SCs differentiation 
retinoic acid-induced. Confocal images obtained using MitoTracker Red (MTR) or TMRM for 
mitochondrial labeling and DAPI or Hoechst for nuclear labeling show alterations in 
mitochondrial morphology between P19SCs and P19dCs, growing in monolayer and in 
spheroids (3D) (Taken from I, Vega-Naredo et. al. 
8
 with permission – Appendix 2) 
 
 
1.3 – Cardiolipin 
 
Cardiolipin (CL) is one of the most important phospholipid in mitochondrial 
membranes. CL was first isolated from beef heart
53
, and due its particular structure, it 
has been subjected to numerous investigations. In mammalian tissues, CL is 
characteristically associated with the inner mitochondrial membrane
54
 and is intimately 
associated with, a number of key mitochondrial enzymes including cytochrome c 
oxidase, ATP/ADP exchange protein, FoF1 ATP synthase and cytochrome bc1 
complex
55
. 
 
 
1.3.1 - Cardiolipin biosynthesis  
Cardiolipin is synthesized in a series of steps from phosphatidic acid ans is 
remodeled into a form which, in the heart, is rich in linoleic acid (18:2). In mammalian 
11 
 
tissues, CL biosynthesis occurs via the cytidine diphosphate-diacylglycerol (CDP-DG) 
pathway (Figure 1.4). In the first step of this pathway phosphatidic acid (PA) and 
cytidine 5-triphosphate (CTP) are converted to CDP-DG; then, the conversion of CDP-
DG and glycerol 3-phosphate to phosphatidylglycerol (PG) occurs by the sequential 
action of phosphatidylglycerol phosphate (PGP) synthase and PGP phosphatase. In the 
final step of the pathway, PG is then converted to CL via condensation with CDP-DG 
catalyzed by CL synthase. Newly synthesized PA and PG may be preferentially utilized 
for CL biosynthesis in the heart
56
. In addition, separate pools of PG, including an extra-
mitochondrial pool not derived from new phosphatidylglycerol biosynthesis, may be 
utilized for cardiac CL biosynthesis. After the remodeling of the four saturated acyl 
chains of CL synthesized, more unsaturated fatty acyl chains are incorporated given to 
the CL a high degree of symetry
57
. Tafazzin, the gene product of TAZ1, is a key player 
in the remodeling of newly synthesized CL, functioning as a monolysocardiolipin 
(MLCL) transacylase
58
. The remodeling is initiated by a phospholipase, which is 
identified in mammalian cells as phospholipase A2 (PLA2), an enzyme that supply the 
lysocardiolipin acceptor substrate for acylation/transacylation remodeling reactions 
necessary for the generation of symmetric tetra-18:2 CL molecular species
59
. 
Furthermore, it was observed that the accumulation of MLCL, resulted from impaired  
taffazin activity, can compromise the remodeling of CL even the process was already 
initiated
59
. On the other hand, the catabolism of CL may occur by the catalysis 
of phospholipase A2 which removes fatty acyl groups or by phospholipase D which 
hydrolyses CL to PA.  
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Figure 1.4 - Pathways of cardiolipin (CL) biosynthesis and remodeling, in mammalian 
cells. See text for details. CDP-DAG, cytidinediphosphate-diacylglycerol; CDS, CDP-DAG 
synthase; CS, CL synthase; DLCL, dilyso-CL; MLCL, monolyso-CL; MLCLAT, MLCL 
acyltransferase; PG, phosphatidylglycerol; PG-P, PG phosphate; PGPP, PG-P phosphatase; 
PGPS, PG-P synthase; PLA2, phospholipase A2; TA, transacylase. 
 
1.3.2 - Role of cardiolipin in mitochondria  
 
The exclusive presence of CL in bioenergetics membranes allows its interactions 
with the electron transport chain complexes involved in oxidative phosphorylation. 
Indeed, CL is required for optimal activity of complex I (NADH dehydrogenase), 
complex II (Succinate dehydrogenase), complex IV (cytochrome c oxidase) and 
complex V (ATP synthase), four large complexes integrated in the inner mitochondrial 
membrane
60
. It was also proposed that cytochrome c release from mitochondria requires 
first the dissociation of its interactions with CL
61
, triggering the downstream events in 
apoptosis. This peculiar phospholipid can also have a very important role in different 
pathologies, particularly in Parkinson and Alzheimer diseases, in which the content of 
CL decreases with age
62
, in heart failure
63
, in diabetes
64
, in cancer
65
, and in Barth 
syndrome, a rare and often fatal X-linked genetic disease that is associated with 
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cardiomyopathy
66
. Barth syndrome is associated to a mutation in the gene coding 
for tafazzin. Mutations in tafazzin results in abnormal CL species which leads to ATP 
depletion and finally could affect the function of the cardiomyocytes.  
Oxidative stress and lipid peroxidation have been associated with several 
diseases and disorders. The abundance of double bonds in its structure turns CL more 
susceptible to peroxidation
67
, and its close association with respiratory chain proteins, 
are known to be a major source of reactive oxygen species (ROS) in mitochondria
68,69
. 
In fact, numerous studies indicate that peroxidized CL is unable to support the 
reconstituted activity of mitochondrial respiratory enzymes
68,70,71
. The pathological 
consequences of CL compositional changes have been associated to shifts in acyl chain 
remodeling pathway (Figure 1.2) Indeed, a reduction in the bioavailability of 18:2, 
essential fatty acid, or alterations in the activity or acyl-specificity of putative CL 
remodeling enzymes may result in aberrant CL. The acyl composition of CL is well 
known to be sensitive to FA composition of the diet which could result in mitochondrial 
respiratory dysfunction
72
. Hence, the involvement of CL in the mitochondrial enzymes 
activity and apoptosis mechanisms converts this phospholipid in an important 
component to study the mechanisms of resistance in cancer stem cells. 
 
 
1.4 - Melatonin  
 
Melatonin (N-acetyl-5-methoxytryptamine), the main pineal hormone, can also be 
produced in many other organs and tissues
73
. Its hydrophilic and lipophilic 
characteristics allow melatonin to reach any cell, compartment or body fluid
74
. It is 
involved in a variety of physiological functions, including modulation of gene 
transcription
75
, blockage of transcriptional factors
76
 and control of mitochondrial 
activities
77
. Melatonin attenuates oxidative stress acting as a direct free radical 
scavenger and stimulating the activity and expression of antioxidant enzymes
78,79
.
 
In 
addition to controlling redox metabolism and circadian and seasonal rhythms, many 
other functions have been attributed to melatonin: influences immune system
80
 
modulates mitochondrial activity
77
 cell death
81
 and autophagy
82
, and presents 
antitumoral properties
83
. Melatonin exerts strong anti-tumor activity via several 
mechanisms, including anti-proliferative and pro-apoptotic effects in addition to its 
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potent antioxidant activity. On mitochondria from normal cells, the physiological 
effects of melatonin are mainly to prevent mitochondrial impairment, energy failure, 
and apoptosis in oxidatively-damaged mitochondria
77 
what could provide a new 
homeostatic mechanism regulating mitochondrial function. Despite this array of 
information, there are studies regarding the effects of melatonin on CSCs in different 
stages of differentiation. 
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Given the relevance of mitochondrial metabolism for stemness maintenance, the 
mitochondrial control of apoptosis and the importance of cardiolipin for mitochondrial 
function and dysfunction, the study of cardiolipin in during CSCs differentiation is of 
great interest for understanding their resistance to therapies. 
 
Therefore, the main objective of the present work was to examine cardiolipin 
remodeling during the differentiation of P19 stem cells under different metabolic 
conditions to understand if cardiolipin alterations occur during cell and metabolic 
remodeling toward a more oxidative condition.  
 
  In addition, since the effects of melatonin in  cancer cells expressing stem cell-
like characteristics are not known, we also analyzed the effects of this indolamine in the 
P19 CSCs model, when administered alone or in combination with DCA. 
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3.1 - Reagents and kits  
 
Reagents used in cell culture, such as 0.05% Trypsin-EDTA (25300-062) and 
fetal bovine serum (FBS; 16000-044) were purchased from Invitrogen (Carlsbad, CA, 
USA) while Dulbecco’s modified Eagle’s medium (DMEM) -high glucose (D5648), 
sodium bicarbonate (S5761), sodium pyruvate (P5280), galactose (G5388), glutamine 
(G3126) and antibiotic/antimycotic solution (A5955), retinoic acid (R2625) as well as 
DMEM free-glucose (D5030)  and trypan blue (T8154)  were obtained from  Sigma, 
(St. Quentin Fallavier, France). The standards polar lipids used in the separation of the 
different classes of phospholipids were obtained from Avanti Polar Lipids, Inc (Delfzyl, 
The Netherlands). The RIPA buffer used for total protein harvesting was purchased 
from Thermo Fisher and PIC (P8340), PMSF (P7626) and DTT (D9779) were obtained 
from Sigma Sigma-Aldrich (St. Louis, MO, USA). The protein quantification 
bicinchonic acid assay (BCA) was performed using the pierce BCA assay kit from 
Thermo Fisher Scientific (23250; Lafayette, CO, USA). Additionally, the Laemmli 
buffer was purchased from BioRad (161-0737; Hercules, CA, USA). 
Agents used for citotoxicity assays such as hydrogen peroxide (121076) were 
purchase from Panreac, Barcelona, Spain, and melatonin (M5250) and dichoroacetate 
(347795) were acquired from Sigma-Aldrich (St. Louis, MO, USA). 
  Moreover, precision plus protein dual color (161-0374) molecular weight 
standard and the blotting-grade blocker non-fat dry milk (170-6404) were obtained from 
BioRad (Hercules, CA, USA). In addition, membrane protein detection was achieved 
using the Enhanced Chemi-Fluorescence system (ECF) from GE Healthcare (RPN3685; 
Buckinghamshire, UK). All primary antibodies used are listed in Table 3.1 as well as 
their respective catalog number and brand; the secondary antibodies used were all 
purchased from Santa Cruz Biotechnology (CA, USA). 
Acridine Orange 10-nonyl bromide (NAO) was obtained from Sigma-Aldrich 
(A7847; St. Quentin Fallavier, France). 
All general chemicals used were of the highest grade of purity commercially available. 
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3.2 - Cell culture 
 
P19 embryonal carcinoma cells were obtained from the American Type Culture 
Collection (ATCC, CRL‐1825) and cultured in glucose- or galactose (glucose free)-
containing media at 37 ºC in a 5% CO2 atmosphere. Cells were cultured in DMEM -
high glucose supplemented with 10% FBS, 1.8 g/l sodium bicarbonate, 110 mg/l 
sodium pyruvate and antibiotic/antimycotic solution. Galactose (glucose-free) medium 
was prepared using DMEM without glucose supplemented with 10% FBS, 1,8 g/l 
sodium bicarbonate, 110 mg/l sodium pyruvate, 1.8 g/l galactose, 0.584 g/l L-glutamine 
and antibiotic/antimycotic solution. For routine subculturing, cells were first rinsed with 
1x PBS (0.137 M NaCl, 2.7 mM KCl; 1.4 mM KH2PO4; 0.01 M Na2HPO4) and then 
incubated with 1 volume of trypsin-EDTA for 3 min at 37°C. Trypsin activity was 
inhibited by the addition of 1 volume of complete growth medium and the final volume 
centrifuged at 300 g for 3 min at room temperature. An appropriate aliquot of the cell 
suspension was added to new culture flasks to obtain cultures between 2x10
3
 and 1x10
4
 
viable cells/cm
2
. This procedure was repeated when cultures reached 80-90% 
confluence. Cells were used between passages 5 and 25. 
 
 
 
3.4 - Cell differentiation and treatment 
 
To initiate differentiation, P19 cells were seeded, in 100 mm dishes culture at a density 
of 5.2x10
3
 cells/cm
2
 and 1 µM RA was added for 96 hours. The procedure was 
performed in absence of light to prevent loss of acid proprieties. The stock of RA 
(100mM) was prepared by the addition of DMSO. After differentiation, cells were 
seeded and allowed to grow for 24 hours before further experiments.    
The cells were exposed, twenty-four hours after sedding, to 500 µM and 1mM H2O2 
during 2, 4 and 6 hours. Melatonin was dissolved in ethanol and DCA in water. Twenty-
four hours after seeding, cells were exposed to 0.1 mM and 1 mM melatonin alone or in 
combination with 10 mM DCA during 72 hours. Controls were always treated with the 
same amount of vehicle (less than 0.95 % ethanol). 
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3.5 - Lipid extraction 
 
The cells were washed with ice-cold PBS, scraped into 5 mL ice-cold PBS, and cell 
pellet was obtained by centrifugation at 200g for 4 min. The final cell pellet was re-
suspended in 1 mL dH2O. Total lipids were extracted by the Bligh and Dyer method
84
. 
Briefly, 3.75 mL chloroform–methanol 1:2 (v/v) and a low amount of BHT (5 µg/ml) 
were added to the cell suspension, vortex the mixture well, and incubating on ice for 30 
min. An additional 1.25 mL chloroform was then added and, finally, 1.25 mL dH2O. 
After vigorous vortex mixing the samples were centrifuged at 1000 g for 5 min at room 
temperature to obtain a two phase system: the aqueous top phase and organic bottom 
phase from which lipids were obtained. The total lipid extracts, recovered from the 
bottom phase, were dried under N2 gas and stored at −20 °C. 
 
 
3.6 - Lipid separation 
 
Total lipid extracts were separated into different classes by thin-layer chromatography 
(TLC). Several spots corresponding to 30 μg total lipid extract dissolved in chloroform 
were applied to a TLC plate. We used TLC plates with concentrating zone 20cm×20 
cm, 0,65mm (Merck, Darmstadt, Germany). Before separation, plates were washed with 
chloroform-methanol and after drying sprayed with 2.3% boric acid in ethanol and 
subsequent exposure to high temperature (100ºC for 15 min). The plates were 
developed with chloroform–ethanol–water–triethylamine 30:35:7:35 (v/v) as mobile 
phase. Lipid spots on the silica plates were observed by spraying the plates with 
primuline (5mg/100ml) and identified (UV lamp at 260 nm) by comparison with 
authentic lipid standards. Then, classes from five spots were scraped off the plates: one 
spot was quantified with the phosphorus assay, and four spots were extracted with the 
use of chloroform/methanol (2:1) (v/v) for subsequent identification by mass 
spectrometry (MS).  
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3.7 - Phospholipids quantification  
 
Phospholipids in lipid extracts or in chromatographic fractions were estimated by 
phosphorus determination through an acidic digestion. The released inorganic 
phosphate was reacted with ammonium molybdate, with the complex giving a strong 
blue color. To evaluate the phospholipid content, phosphorus assay was performed by a 
method described elsewhere
85
. Briefly, 500 µl perchloric acid (70%) was added to 
phosphate standards of KH2PO4 (1-5ug) and samples (25 µl; 50 µl and 100 µl) 
previously dried. The samples were incubated for 1 hour at 180 °C, followed by cooling 
to room temperature. Then, 3.3 ml of water, 0.3 ml ammonium molybdate, and 3.3 ml 
ascorbic acid were added to the standards and samples, which were then incubated for 
10 min at 100 °C in a water bath. The classes from spots scraped to silica plates were 
centrifuged for 5 min at 1000 g to separate PLs from silica. Finally, the standards and 
samples solutions were measured at 800 nm. These experiments were performed at least 
in triplicate, from different cell culture obtained on different days. The relative 
abundance of each PL class was calculated by relating the amount of PL class with the 
total amount of PL in the sample. 
 
 
3.8 - Silica extraction 
 
 In order to analyze the different phospholipid classes by mass spectrometry, TLC spots 
corresponding to all identified classes were scraped off from the plates with the help of 
a spatula to a piece of aluminum paper, and then transferred to a glass tube. Four 
hundred and fifty μL of chloroform was added of all tubes, vortexed well and left to 
stand for 5 min, in order to be able to extract the phospholipids from the silica. Then, 
samples, were filtered under vacuum with a sand plate funnel; 450 μL of 
chloroform/methanol 1:1 (v:v) were added to the tubes, vortex well and then filtered 
again. After each sample the filter was thoroughly washed with methanol, and was 
changed every two filtered samples. The filtered samples were dried under nitrogen 
flow and were re-suspended in 100 μL of chloroform to mass spectrometry analysis, or 
stored at -4ºC for further analysis. 
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3.9 - Electrospray mass spectrometry  
 
Analysis of CL was carried out in negative modes on electrospray (ESI) linear ion trap 
mass spectrometer (ThermoFinnigan, San Jose, CA, USA), and electrospray triple 
quadrupole mass spectrometry (Walters, Manchester, UK). The samples for electrospray 
analysis were prepared by diluting in 20µl CL (obtained after extraction from silica and 
re-suspended in 100 µl of chloroform) with 200 µl of methanol. 
The samples were introduced into the mass spectrometer using a flow rate of 8 µl/min. 
ESI conditions in electrospray linear ion trap mass spectrometer were also as follows:, 
voltage, 4.7 kV, capillary voltage -34.9 V, tube lens voltage -124.9 V, capillary 
temperature 275ºC, and the sheath gas flow was 25 units. Isolation with an interval of 
0.5 Da was used with a 30 milliseconds activation time for MS/MS experiments. 
Full scan MS spectra and MS/MS spectra were acquired with 50 and 200ms maximum 
ionization time. Normalized collision energy (CE) was varied between 17 and 20 
(arbitrary units) for MS/MS. Data acquisition of this mass spectrometer was carried out 
using an Xcalibur data system (V2.0). 
 
 
3.10 - Citrate synthase activity 
 
Citrate synthase is the initial enzyme of the tricarboxylic acid (TCA) cycle and an 
exclusive marker of the mitochondrial matrix. The enzyme catalyzes the reaction 
between acetyl coenzyme A (acetyl CoA) and oxaloacetic acid to form citric acid. The 
hydrolysis of the thioester of acetyl CoA results in the formation of coenzyme A with a  
thiol group (CoA-SH) which when reacts with the DTNB form the 5-thio-2-
nitrobenzoic acid (TNB) , which exhibits maximum absorbance at 412 nm. 
After sonication, P19 cells (5 μg) were incubated in 0.9 ml of 50 mM potassium 
phosphate (pH 7.4) at 21 ºC in the presence of 100 μM DTNB and 100 μM acetyl CoA. 
The citrate synthase reaction was initiated by the addition of 100 μM oxaloacetate and 
monitored by the spectrophotometric, at 412 nm. The intensity of the absorbance is 
proportional to citrate synthase activity.  
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3.11 - Sulforhodamine B assay 
 
This method is based in the ability of the bright pink aminoxanthene SRB dye with two 
sulfonic groups to bind to cell proteins under mildly acidic conditions
86
. Under these 
conditions, SRB binds to protein basic amino acid residues in acid-fixed cells to provide 
an estimate of total protein mass, which is related to cell number. Accordingly, this 
assay allows to indirectly accessing cell proliferation and viability. Moreover, once pH 
is alkalinized, basic amino acids became protonated and the SRB dye is released into 
the solution allowing its spectrophotometry measure.  
P19 cells were seeded in in 48-well plates at a concentration of 0.5x10
4
 cells/ml for P19 
CSCs and 2x10
4
 cells/ml for P19 dCCs. Twenty-four hours after seeding, cells were 
treated with hydrogen peroxide (H2O2) (500µM and 1mM). Following treatment (0h, 
2h, 4h and 6h), the incubation media were removed and cells were fixed in 1% acetic 
acid in 100% ice-cold methanol for at least 2h at -20ºC. The cells were then incubated 
with 0.5% (wt/vol) SRB in 1% acetic acid for 1 h at 37°C, and subsequently washed 
three times with 1% acetic acid to remove unbound staining. Then, 500 µl of Tris 
10mM, pH 10 was added and the plates were incubated at room temperature in orbital 
shaking platform for 30 min in order to solubilize bound-protein. Finally, 200μL of the 
solubilized solution was transferred to a standard 96-well plate and its absorbance read 
in a VITOR X3 microplate reader (Perkin Elmer, Waltham, MA, USA) working at 
room temperature with a 544/15 nm filter. 
 
 
3.14 - Trypan blue dye exclusion assay 
 
In this work, a trypan blue dye exclusion assay was performed to analyze the cell 
viability after treating cells with melatonin. Treated and control P19 cells were 
trypsinized and washed with PBS. The cell suspension (100 µl) was aseptically 
transferred to a 1.5 ml tube and an equal volume of trypan blue was added for 3 minutes 
at room temperature. The re-suspension was then placed in a dual-use counting slide 
(145-0011, Bio-Rad; Hercules, CA, USA) and read in a TC20 automated cell counter 
(145-0102SP, Bio-Rad).  
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3.12 - Protein Quantification 
 
Protein was quantified using the bicinchoninic acid assay (BCA) following 
manufacturer instructions. Working Reagent was prepared in a proportion of 50 parts of 
BCA reagent A to 1 part of reagent B. The reaction was initiated by adding 200 μL of 
working reagent to 8 μL of sample diluted 1:5 in ultrapure water, in a standard 
polystyrene flat bottom 96-well microplate. After 30 min incubation at 37°C, 
absorbance was read in a VICTOR X3 plate reader (Perkin Elmer Inc.) using a 544/15 
nm filter. The standard curve ranging from 25 to 2000 μg/ml was made using a solution 
of BSA standard vials included in the referred kit. Standards and unknown samples 
were performed in duplicates. 
 
 
3.13 - Western blot analysis 
 
In order to obtain total cellular extracts, P19 cells were harvested by trypsinization, 
washed with PBS and centrifuged for 5 min at 1000 g. The cellular pellet was re-
suspended in RIPA buffer supplemented with 2 mM DTT, 100 μM PMSF, and a 
protease inhibitor cocktail (containing 1 μg/ml of leupeptin, antipain, chymostatin, and 
pepstatin A), physically ruptured by sonication and kept at -80 ºC until used.  
After protein quantification, samples were diluted in a Laemmli buffer (62.5mM Tris 
pH 6.8 (HCl), 2% SDS, 50% Glycerol, 5% β-mercaptoethanol, 0.04% bromphenol 
blue). Protein lysates were then boiled at 95ºC for 5 min. The previous steps led to 
protein denaturation and therefore loss of quaternary, tertiary and secondary protein 
structure allowing separated solely as a function of their molecular size. The separating 
gel consisted in 12% acrylamide/bis, 375mM Tris pH 8.8 (HCl), 0.1% SDS, 0.05% 
TEMED and 0.05% APS while stacking gel consisted in 4% acrylamide/bis, 126mM 
Tris pH 6.8 (HCl), 0.1% SDS, 0.1% TEMED and 0.05% APS. Different final 
acrylamide/bis percentages were used depending on the molecular size of the proteins of 
interest allowing a maximum separation resolution.  
Equivalent amounts of protein (25-50 μg) were separated by electrophoresis using a 
Mini-PROTEAN 3 Cell (Bio-Rad) filled with running buffer (25mM Tris, 192mM 
glycine, 0.1% SDS) and connected to a PowerPac Basic Power Supply (Bio-Rad) 
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outputting a constant voltage of 150V. Separation was carried out at room temperature 
and until the front of the run reached the bottom end of the gel. A molecular weight 
standard (Precision Plus Protein Dual Color Standards, from Bio-Rad) was included to 
allow molecular weight estimation. 
Once protein separation was complete, proteins were transferred to a thin surface layer 
of pre-activated (5 sec in 100% methanol followed by 15 min in 25mM Tris, 190mM 
glycine and 20% methanol) 0.45μm polyvinylidene difluoride membrane (PVDF, 
Millipore, Billerica, MA, USA), by an electric current passed through the gel.  
Ponceau S staining was used to ensure equal loading. Once protein transfer was 
complete the membranes were blocking with 5 % skim milk in TBS-T (50 mM Tris–
HCl, pH 8; 154 mM NaCl and 0.1 % Tween-20) or 5% of BSA in TBS-T for 1 h at 
room temperature or overnight at 4ºC, depending of antibody  manufactures description. 
Then, membranes were incubated overnight at 4 º C with the antibodies (see in Table 1). 
After three 15 min washes in TBS-T, the membranes were incubated with a dilution 
(1:5,000 in blocking buffer) of a corresponding alkaline phosphatase-conjugated 
secondary antibody (Santa Cruz Biotechnology) for 2 h at room temperature. After three 
15 min washes in PBS-T, membranes were developed with the ECF detection system 
(RPN5785; GE Healthcare, Piscataway, NJ) and imaged with Versa Doc imaging 
system (Bio-Rad) according to the manufacturers’ protocols. Densities of each band 
were calculated with Quantity One Software (Bio-Rad). All data presented are 
representative from at least three separate experiments. 
 
Table 1 – List of primary antibodies used in Western Blot protein analysis. 
 
 
 
 
Code Dilution 
Host 
Species 
Molecular 
weight (KDa) 
% 
polyacrilamide 
Catalog 
Number 
Manufacturer 
AIF  1:1000 Mouse 57 12 sc13116 Santa Cruz 
CLS1 1:500 Goat 33.5 14 orb125195 Biorbyt 
Taffazin 1:500 Goat 30 14 sc49760 Santa Cruz 
TOM20 1:1000 Rabbit 20 12 sc11415 Santa Cruz 
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3.15 - Lipid peroxidation 
 
Measurement of malondialdehyde (MDA) is a widely used as an indicator of lipid 
peroxidation. MDA reacts readily with amino groups on proteins and other 
biomolecules to form a variety of adducts, including cross-linked products.  
The levels of MDA were measured by high performance liquid chromatography 
(HPLC) separation. P19 cells were harvested, washed and re-suspended in 50 mM 
phosphate buffer (pH 7.4) and stored at -80ºC until used. Then, levels of lipid 
peroxidation were assessed by the fluorymetric determination (excitation at 515 nm and 
emission at 553 nm; FP-2020/2025, Jasco, Tokyo, Japan) of MDA adducts separated by 
HPLC (Gilson; Middleton, WI, USA) using the ClinRep complete kit (RECIPE; 
Munich, Germany). 
 
 
3.16 - Cardiolipin peroxidation 
 
In this present work, CL peroxidation was measured using the 10-N-nonyl acridine 
Orange (NAO) fluorescent probe. NAO is able to bind with high affinity to non-
oxidized cardiolipin (green-fluorescence). When in the presence of oxidized CL, NAO 
has been reported to bind with a decrease affinity reflected by lower green 
fluorescence
87,88,89
. We thus analyzed the loss of the fluorescence peak of NAO that is 
proportional to an increase of CL peroxidized levels.  
 For the assay, cells were seeded in 100mm plates at a concentration of 0.5x10
4
 cells/ml 
for P19 CSCs and 2x10
4
 cells/ml for P19 dCCs. Twenty-four hours after seeding, group 
of cells were treated with different compounds: H2O2 (500 µM) during 4h, melatonin (1 
mM) and DCA (10 mM) during 72h. After that, cells were washed, trypsinized and 
centrifuged at 210g for 10 minutes ate 4°C. The cell pellets were washed in 1ml of PBS 
and centrifuged again. The resultant cell pellets were re-suspended in 0,1 µM of NAO 
in PBS, incubated for 30 minutes at 37°C /5% CO2 in the dark. Then, cells were 
centrifuged at 210xg for 5 minutes at 4°C and the cell pellet was re-suspended in 0,3ml 
of PBS and transferred to FACS tubes. The cell suspension (20,000 cells) was analyzed 
by FACSCalibur flow cytometer (Becton Dickinson, San Jose, California, USA) at low 
(12 μL/min) sample flow rate. Data was analyzed using BD CellQuest Pro software 
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package (version 5.2). The fluorescence excitation of NAO were measured at 488nm 
while the fluorescence emission at 530±15 nm. Two regions were defined, M1 and M2, 
based on the fluorescence of P19SCs that presented a decrease peroxidized CL and thus, 
a higher NAO fluorescence. The appearance of a peak in M1 region towards loss of 
fluorescence in M2 region indicated an increase of CL peroxidation. All the other 
conditions were compared based on those regions.    
 
 
3.17 - Isolation of mitochondrial and cytoplasmatic extracts 
 
To collect mitochondrial extracts, P19 cells were harvested by trypsinization and spin 
down at 1000xg. Pellets were washed once in cold PBS and centrifuged again. The cell 
suspension was then re-suspended in 0.5ml of ice cold sucrose buffer (250 mM sucrose, 
20 mM K
+
 Hepes pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 1 mM EGTA) 
supplemented right before use with 1mM DTT, 0.1mM PMSF and protease inhibitor 
cocktail containing 1µg/ml of leupeptin, antipain, chymostatin and pepstatin. Then, the 
suspension was incubated on ice for 20 to 30 minutes. After the incubation, the 
suspension were transferred to a pre-cooled Potter–Elvehjem homogenizer with a 
TeXon pestle and homogenized 30 times using a tight pestle, while keeping the 
homogenizer on ice. The progress was monitored every 20 to 30 strokes under a phase 
contrast microscope and was stopped when more than 90% of cells were burst. 
Homogenized cells were centrifuged at 3500 g for 5 minutes at 4ºC (Evolution RC, 
Sorvall, USA). The supernatant was collected containing mitochondrial and cytosolic 
fraction. Then, the supernatant was centrifuged again at 10,000 g during 15 minutes at 
4ºC. The pellet, corresponding to the mitochondrial fraction, was re-suspended in 50µl 
of sucrose buffer cited above. The supernatant was again centrifuged at 100,000xg 
during 30 minutes at 4ºC (Beckman TL-100 Ultracentrifuge, USA) The resulting 
supernatant contains the cytosolic fraction and in order to concentrate the protein was 
lyophilized and re-suspended in 50µl of the same sucrose buffer. 
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3.18 - Statistical analysis  
 
Data were expressed as mean values ± standard error of mean for a number of 
independent experiments, specific for each case. Statistical comparisons between P19 
CSCs and P19 dCCs were carried out using a Student's t test. The non-parametric test 
Mann-Whitney was applied to non-normal data. Multiple comparisons were performed 
using one-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test 
if the F-values were significant. Significance was accepted with p<0.05.
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4.1 - Lipidic profile of P19 cells 
 
Due to the importance of CL, in a variety of pathological settings and its association to 
the mitochondrial metabolic processes, the study of CL remodeling during cancer stem 
cells differentiation seems be important. For this reason, we evaluated the lipid profile 
in undifferentiated and differentiated P19 embryonal carcinoma cells. We also analyzed 
the lipidic profile when mitochondrial ATP production was forced by growing cells in a 
galactose, glucose-free, pyruvate/glutamine media. 
 
Phospholipid classes were fractionated by TLC and each class was identified by 
comparison with applied standards. To evaluate the variation of phospholipid content 
each spot was quantified using phosphorous assay and the results are shown in figure 
4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 - Profile of different phospholipids in P19 EC cells. Phospholipid (PL) content of 
the four types of P19 cells: stem (CSCs) and differentiated (dCCs) lines, growing in glucose 
(Glu) and in galactose (Gal)-containing media. PC – phosphatidylcholine, PI – 
phosphatidylinositol, PS – phosphatidylserine, PE – phosphatidylethanolamine, CL– 
cardiolipin. Relative abundance of phospholipid refers to the percentage of phospholipid 
phosphorus recovered from respective TLC. * vs. Glu-CSCs; # vs. Gal-CSCs. Data represent 
the average percentage of PL content ± SEM from at least five independent experiments  The 
number of symbols denotes statistical significance: one for p<0.05, two for p<0.01 and three for 
p<0.001. 
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In all samples, phosphatidylcholine (PC) represented the dominant phospholipid class of 
total phospholipids followed by phosphatidylethalonamine (PE). Additionally, other 
phospholipids were also detected with the following order of abundance: 
phosphatidylserine (PS) > phosphatidylinositol (PI) > CL – in Glu-CSCs; PS/PI > CL – 
in Gal-CSCs; and PI > PS > CL – in Glu-dCCs and Gal-dCCs. No significant variations 
between groups were observed for CL content. The content of PC was decreased with 
the increase in the degree of differentiation being lowest in the P19 cells with the 
highest differentiation stage, P19 Gal-dCCs. On the contrary, PI levels were statistically 
increased in cells with maximum mitochondrial activity and highest degree of 
differentiation (Gal-dCCs). As show the content of CL and PI were lower in Glu-CSCs 
compared with the others groups of cells. Finally, PE content was only significantly 
increased in Gu-dCCs in comparison with their undifferentiated counterpart, Glu-CSC 
(p < 0.01).  
To complete CL analysis, each spot from P19 Glu-CSCs and Glu-dCCs was studied by 
mass spectrometry to confirm if the absence of significant changes in the total CL 
content is also extended to CL molecular species.  
 
 
 
4.2 – Mass spectrometry analyses for CL species 
 
The characterization of CL molecular species was performed after extraction of silica 
and analyzed by MS in a negative mode. 
CL is located almost exclusively in the mitochondrial inner membrane, is essential for 
normal mitochondrial energy metabolism and has been implicated in the process of 
apoptosis. This phospholipid has a dimeric structure, corresponding to two 
phosphatidylglycerols connected with a glycerol backbone in the center
90
. Cardiolipin 
has four alkyl groups and potentially possesses two negative charges resulting in either 
singly charged [M-H]
−
 or doubly charged [M-2H]
2−
 ions observable in the MS spectra
91
. 
Singly charged CL ions in negative mode were represented by different molecular 
clusters with m/z 1373.8, 1401.7, 1403.8, 1425.8, 1427.8, 1449.8, 1455.8, 1451.8, 
1479.8, 1501.8 with a variety of fatty acid residues (from C16:0 to C22:6) shown in 
figure 4.2 The ions formed during fragmentation process of CL (a, b, a+56, or b+136) 
were identified in MS
2
 spectra
91
 and are described in Table 1 and shown in figure 4.2, 
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however in that spectra, only the [M-H]− fragmentation of clusters with m/z 1401.8; 
1427.8; 1455.8; 1449.8; 1479.8 are represented. 
The results show evident changes in CL species between both types of P19 cells (Glu-
CSCs and Glu-dCCs). The CL species m/z 1427.8 and 1455.8, attributed to the CL 
(16:1)(18:2)/(18:1)2 and  CL (18:1)4(18:1)2(20:2) respectively, were highly present in 
Glu-CSCs; while in Glu-dCCs, CL species with m/z 1427.8 corresponding to CL 
(16:1)(18:2)/(18:1)2 is the most abundant specie. The relative abundance of the ion m/z 
1403.8 attributed to the CL (16:0)2(18:1)2 had a similar intensities in both types of P19 
cells. Overall, Glu-CSCs were enriched with CL species of m/z 1425.8 and 1449.8 
corresponding to CL (16:1)(18:2)(18:1)2 and (18:1)(18:2)3 respectively,  which were 
absent in Glu-dCCs. These alterations imply that CL species and fatty acid composition 
is rather susceptible to the differentiation of P19 stem cells. Therefore, this CL 
remodeling may have important physiological implications by contributing to the 
mitochondrial remodeling induced during the differentiation of P19 CSCs. 
Figure 4.2 - Representative ESI-MS spectrum in negative mode of CL molecular species of P19 
Glu-CSCs (A) and Glu-dCCs (B) and general structure of CL.
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Table 2. Major CL molecular species from P19 Glu-CSCs and Glu-dCCs. 
 
 
 
 
4.3 - CL synthesis and remodeling  
 
After general evaluation of CL content and species during the differentiation of P19 EC 
stem cells we next analyzed the machinery involved in CL synthesis and maturation. 
For that we measured the content of some proteins associated to those processes 
including cardiolipin synthase (CLS) and taffazin.  CLS is the enzyme that catalyzes the 
final step in the synthesis of CL from phosphatidylglycerol and CDP-diacylglycerol. 
Tafazzin is a transmembrane mitochondrial protein that contributing to cardiolipin 
remodeling modifies and adapts mitochondrial structure and function
59
.  
Western blot analysis shows a significant increase of CLS1 protein content in 
differentiated P19 cells (Glu-dCCs and Gal-dCCs) compared their respective stem 
counterpart (Glu-CSCs and Gal-CSCs). Additionally, higher levels of CLS1 were 
observed in Gal-dCCs in comparison with the differentiated cells grown in glucose 
medium.   
 
 
 
A 
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Figure 4.3 - CL synthesis and maturation in the four types of P19 cells. Levels of protein 
involved in synthesis of CL (CLS1) (A) and taffazin (B), a protein involved in the formation of 
mature CL. Bar charts show means of optical density (O.D.) normalized for Ponceu labeling ± 
S.E.M expressed as percentage of Glu-CSCs, from at least three separate immunoblots. :  * vs. 
Glu-CSCs; # vs. Gal-CSCs; a vs. Glu-dCCs. The number of symbols marks the level of 
statistical significance: one for p<0.05, two for p<0.01 and three for p<0.001. 
 
In addition, we found higher taffazin content in the P19 cells with higher 
differentiation degree. Thus, P19 Glu-CSCs presented the lowest content in taffazin.  
This finding indicates that CL remodeling occurs with cell differentiation being higher 
in the group of P19 cells with more active mitochondrial metabolism and higher degree 
of cell differentiation, P19 Gal-dCCs groups. 
 
 
 
 
 
 
Taffazin (33KDa) 
Ponceu S 
CLS1 (30KDa) 
Glu-dCC Glu-CSC Gal-CSC Gal-dCCs 
A B 
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4.4 – Cardiolipin peroxidation  
 
Apart from analyzing CL biosynthesis and maturation, we also analyzed their oxidation 
in the four groups of P19 cells. For that, we used the fluorescent NAO probe which has 
a high affinity for cardiolipin
92
.   
To evaluate and induce CL peroxidation, we used hydrogen peroxide as a positive 
control. Hydrogen peroxide has important roles as a signaling molecule in the regulation 
of a wide variety of biological processes. Hydrogen peroxide can decompose to a 
hydroxyl radical, a very protect free radical which oxidizes mitochondrial subtracts. For 
that, we initially verified the toxicity of H2O2 in P19 cells using the SRB assay. We 
tested 500 µM and 1 mM H2O2 at different time points (0h, 2h, 4h, and 6h) as 
previously described
93
. 
 
Our results show that all groups of cells were susceptible to H2O2. The results showed 
an increase in the toxic effects of H2O2 with cell differentiation (Glu-CSCs – Glu-dCCs 
– Gal-CSCs – Gal-dCCs). The more undifferentiated cells, Glu-CSCs, presented a more 
resistant profile against H2O2. Taking these results into account, we decided to evaluate 
CL peroxidation on the four types of P19 cells after 4 h of treatment with 500 µM H2O2.   
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Figura 4.4 - Effect H2O2 on cell viability in the four types of P19 cells. Stem (CSCs) and 
differentiated (dCCs) growing in glucose- (Glu) and galactose-(glucose free) (Gal) containing 
medium were treated with 500µM and 1mM of H2O2 during 2, 4 and 6 hours. Cell viability was 
measured using the sulforhodamine B cell mass assay. Data are expressed as percentage of the 
control for time zero. Data are means±S.D rom n±5. *: p<0.05; **p<0.01; ***: p<0.001 versus 
control.  
   
Cardiolipin has emerged as an essential lipid in controlling the mitochondrial-dependent 
steps that lead to the release of apoptogenic factors. CL has been described to have an 
anti-apoptotic function, binding cytochrome c to the mitochondrial inner membrane and 
thus preventing its release to the intermembrane space
94
. In this scenario, the 
peroxidation of CL has been shown to lessen the binding of cytochrome c to the inner 
mitochondrial membrane and facilitate permeabilization of the outer membrane
95
. In 
this work, we evaluated CL peroxidation in the four different differentiation stages of 
P19 cells using the NAO specific probe.  As shown in figure 4.4A, the loss of NAO 
fluorescence, what reflects higher CL peroxidation, is shown as a disappearance of the 
NAO peak signal from region M2 to region M1.  
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Figure 4.5 - Levels of CL peroxidation in P19 EC cells. The CL peroxidation was monitored 
by loss of NAO fluorescence measured by flow cytometry. The four group of cells were 
incubated with 0.1µM of NAO. As positive control, P19 cells were previously incubated for 4h 
with 500µM of H2O2. (A) Representative graphics show the loss of NAO fluorescence peak 
towards the increase of M1 region peak. (B) The % cells gated in M1 region indicates the 
increased of CL oxidation and the results show an increase of CL peroxidation in differentiated 
cells (Glu-dCCs and Gal-dCCs). Data are means ± S.E.M. from n±6. ***: p<0.001 versus 
control; 
aaa
: p<0.001versus Glu-CSCs and 
bbb
: p<0.001 versus Gal-CSCs. 
A 
B 
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Our results shown as the percentage of cells with oxidized CL (cells gated on M1 
region) revealed evident differences, regardless the culture media used, between stem 
(Glu-CSCs and Gal-CSCs)  and differentiated (Glu-dCCs and Gal-dCCs) P19 cells what 
might be a consequence of a different  mitochondrial redox status generated by the RA-
induced mitochondrial remodeling
79
. Thus, Glu-CSCs and Gal-CSCs showed lower 
levels of peroxidized CL (p < 0.001) (Figure 4.5). The treatment with H2O2 increased 
the number of cells in the M1 region in the four groups of P19 cells (p < 0.001). 
However, the effect of H2O2 on CL peroxidation was more limited in dCCs probably 
because their CL is almost oxidized. 
 
 
4.5 – Melatonin effects on the P19 cancer stem cell model  
 
Melatonin, the main pineal hormone, is known to act as a potent antioxidant by 
scavenging free radicals and stimulating the activity and expression of antioxidant 
enzymes. In addition, melatonin has other important roles in mitochondrial activity
77
, 
cell death
81
 and presents strong antitumoral properties
83
.  The protective effects of 
melatonin may be produced through its action at mitochondrial level, in which oxidation 
and/or depletion of CL could play a critical role
96
. 
 
To assess the effect of 0.1 and 1 mM melatonin on the four stages of differentiation of 
P19 cells (Glu-CSCs, Glu-dCCs, Gal-CSCs and Gal-dCCs), we evaluated cell viability 
using the trypan blue dye assay after 72 hours of treatment. Intriguingly, our results 
showed that the antiproliferative effect of melatonin was dependent on the culture 
medium used for cell growth. At 72 hours of incubation, 1 mM melatonin significantly 
inhibited Gal-CSCs and Gal-dCCs proliferation. Thus, only the cells grown in galactose 
(glucose free)-containing media which rely in oxidative metabolism for ATP production 
were sensitive to 1 mM melatonin (p < 0.01). Due to this, one can ask what makes these 
cells prone to melatonin in comparison with the resistant counterparts grown in high 
glucose medium (Figure 4.6). 
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Figure 4.6 - Effects of melatonin in cell viability in P19 EC cells. Cell viability determined 
by trypan blue dye exclusion assay after 72 hours of treatment with melatonin shows the 
resistance of P19 cells grown in high glucose medium. Data are expressed as percentage of live 
cells ± SEM at least three independent experiments. * vs. control; a vs. Glu-CSCs. The number 
of symbols marks the level of statistical significance: one for p<0.05, two for p<0.01, and three 
for p<0.001. 
 
 
The excessive production of ROS can damage all cells components, possibly leading to 
death pathways. As described, melatonin also presents a pro-oxidant effect in tumor 
cells as tumor leucocytes
97
, lymphoma
98
 and hepatic cancinoma
99
 cells.  Thus, we 
decided to evaluate the lipidic oxidation as an oxidative stress marker. For that, we 
measured the content in malondialdehyde (MDA), a ROS-induced lipid peroxidation 
product. 
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Figure 4.7- Effect of melatonin on lipid peroxidation in the four groups of P19 EC cells. 
Measurement of malondialdehyde (MDA) by high-performance liquid cromatography in P19 
embryonic carcinoma stem (CSCs) and differentiated (dCCs) cells, grown in glucose (Glu) and 
galatose (Gal) media, after 72 hours of treatment with 0,1 and 1 mM melatonin Statistical 
comparisons:  * vs. control; # vs. 0.1 mM melatonin; a vs. Glu-CSCs; b vs. Gal-CSCs; c vs. 
Glu-dCCs. The number of symbols marks the level of statistical significance: one for p<0.05, 
two for p<0.01 and three for p<0.001. 
 
 
Both groups of P19 differentiated cells (Glu-dCCs and Gal-dCCs) presented a major 
content of MDA when compared to their stem counterparts (p < 0.001) and the cells 
grown in galactose (Gal-CSCs and Gal-dCCs) also present a higher MDA levels when 
compared to their glucose-cultured counterpart (p < 0.01) (Figure 4.7). Despite these 
basal differences, we found that 1mM melatonin significantly increased the amount of 
MDA in all groups of P19 cells when compared to their controls, especially in cells 
grown in galactose medium (p < 0.001) (Figure 4.7). Therefore, this evident prooxidant 
effect may probably be related to the capacity of melatonin in decreasing the 
proliferation rate of P19 cells with an active oxidative metabolism. Thus, the prooxidant 
mechanism of action of melatonin seems to be dependent on the mitochondrial 
metabolism. 
Since excessive ROS production by mitochondria is involved in triggering intrinsic cell 
death pathways and melatonin increase the lipid-peroxidation in in P19 cells with higher 
mitochondrial metabolism, we looked to the effect of melatonin in CL peroxidation.  
46 
 
Glu-CSCs presented a resistant profile against melatonin which seems to be closely 
associated to their glycolytic metabolism. As recently described by our group, there is 
also a resistant profile of Glu-CSCs against DCA, an anticancer drug that reverses the 
abnormal metabolism of cancer cells by shifting it from glycolysis to glucose 
oxidation
79
. As melatonin appears to affect only cells relying on mitochondrial 
metabolism we wondered if a combined treatment with DCA could make Glu-CSCs 
prone to melatonin decreasing its proliferation rate. In previously results of our lab we 
saw a susceptibility in Glu-CSCs to the combined treatment and also a synergetic effect 
in both types of P19 cells growing in galactose medium (Appendix 3). So, we wanted to 
verify, in all groups of P19 cells, how melatonin treatment affects the state of CL 
oxidation using the combined treatment. 
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Figure 4.8 - Effects of melatonin on cardiolipin peroxidation.  The four group of cells  
(P19SCs growing and in glucose and galactose (glucose-free) and their differentiated 
counterparts)  were treated during 72h with 1mM melatonin, alone or in combination with10 
mM DCA and  CL peroxidation was monitored by following the loss of NAO fluorescence by 
flow cytometry. (A) Demonstrative histograms show the loss of NAO fluorescence peak 
towards the increase of M1 region peak. (B) The % cells gated in M1 region indicates increased 
of CL oxidation. Data are means ± S.E.M. from n±6: * vs. control; # vs. 1 mM melatonin; a vs. 
Glu-CSCs; b vs. Gal-CSCs. The number of symbols marks the level of statistical significance: 
one for p<0.05, two for p<0.01 and three for p<0.001. 
A 
B 
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Figure 4.8 revealed the treatment with melatonin increased the peroxidized CL in CSCs 
(p<0,001) and the opposite effect in dCCs independently of the culture media. These 
results are shown in the spectra of figure 4.8A with the decreased of NAO fluorescence 
peak in CSCs. Additionally, the combined treatment with melatonin and DCA had the 
same effect in CL peroxidation in CSCs and in differentiated cells comparatively of the 
effect of treatment with melatonin. Thus, melatonin seems prevent the CL oxidation in 
CSCs and so it may not involve in the antiproliferative effects of melatonin observed in 
this type of cells. 
 
In addition to the effects of melatonin on CL peroxidation in P19 cells growing in 
galactose media, previously results of our laboratory showed an absence of caspase-3 
activity and translocations of cytochrome c to the cytoplasm in these cells.  Thus, the 
possible cytotoxic mechanisms of melatonin are through of caspases-independent 
pathway. Independently of caspase activation, cell death can occur with the release of 
endonuclease G (Endo G) and apoptosis inducing-factor (AIF). The basic mechanism of 
AIF-induced cell death consists in its release from the mitochondrial intermembrane 
space to the cytosol and translocation to the nucleus.  
In this work we proposed to verify if the release of the AIF from mitochondria is 
involved in the cytotoxic effect elicited by melatonin in P19 cells. For that, we checked 
the protein content of AIF by western blotting, in mitochondrial and cytosolic fractions 
from P19 cells treated with 1 mM melatonin alone or in combination with 10 mM DCA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 - Cytotoxic effects of melatonin in P19 cells. Representative immunoblot 
images for apoptosis-inducing factor (AIF) in cytosolic and mitochondrial extracts from P19 
stem (CSCs) and differentiated (dCCs) cells, grown in glucose (Glu) and galatose (Gal) media. 
Treatments: control (C), melatonin 1 mM (M), dichloroacetate 10 mM (D), and melatonin 1 
mM + dichloroacetate 10 mM (M+D). Ponceau S was used as cytosolic loading control and 
TOM20 as a mitochondrial loading control. Bar charts show means of normalized optical 
density (O.D.) ± SEM expressed as percentage of CSCs control, from at least three separate 
immunoblots. Statistical comparisons:  * p<0.05; ** p<0.01; *** p<0.001 vs. control.  
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The immunoblot analysis revealed that the treatment with melatonin, alone or in 
combination with dichloroacetate, induces a higher cytosolic localization of AIF in both 
types of P19 cells grown in galactose medium. In addition, although the treatments with 
melatonin also increased the cytosolic expression of AIF in the highly resistant Glu-
CSCs, in melatonin-treated cells grown in galactose medium (Gal-CSCs and Gal-dCCs) 
and in Glu-dCCs treated with melatonin and DCA, we observed an additional cytosolic 
band of ~57 kDa which probably corresponds to the form of AIF described to be 
translocated to the nucleus triggering a caspase-independent type of cell death (Figure 
4.9). 
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Due to the relation of CL with mitochondrial apoptosis, an analysis in CSCs under 
different stages of differentiation would help to elucidate the mechanisms of CSCs 
resistance to mitochondrial targeted-therapies. In this study we compare the remodeling 
of mitochondrial CL during P19 CSCs differentiation. 
CL provides a paradigmatic example for the role of phospholipids in mitochondrial 
structure and function. Recent evidences demonstrated similar mitochondrial mass and 
mtDNA copy number between P19 stem and differentiated cells
47,48,79
. In fact, our 
results demonstrated no significant changes in total CL levels after the differentiation 
induced by the treatment with retinoic acid. However, it is possible to see that P19 cells 
with a more active mitochondrial metabolism present a small increase in total CL. 
These evidences probably result of the increase in the expression of mitochondrial 
respiratory complexes, previously described
79
, which require CL for their assembly in 
mitochondrial membrane. Furthermore, CL form hexagonal phases that can create 
tension in membranes which have functional importance to various mitochondrial 
processes such as membrane fusion or the movement of proteins or solutes across 
membranes
100
. Thus, it is likely that more CL seems be required for the differentiation 
of P19 cells. In agreement with our results, other studies already described, minor 
changes in CL content in carcinoma
101
 and stem cells
102
 differentiation, which was in 
some cases associated to increased mitochondrial activity during this process.  
Although we have not found statistical differences in total CL content after the RA-
induced differentiation, we observed several alterations regarding CL species in P19 EC 
cells grown in glucose medium. In fact, P19 Glu-CSCs possessed a higher incorporation 
of oleic acid (18:1) compared with its differentiated counterpart. This evidence suggests 
that a higher content in non-oxidized CL may protect these cells against apoptosis, 
caused by anti-cancer agents, as previously described
103
.  Contrarily, Glu-dCCs have 
more of palmitoleic and linoleic acids and peroxidized CL which probably make these 
cells more susceptible to apoptosis than Glu-CSCs. In fact, during early stages of 
intrinsic apoptosis, the CL/cytochrome c complexes exhibit a potent peroxidase activity 
and the polyunsaturated species of CL have been identified as a preferential oxidation 
substrate for cytochrome c in vitro
104,105 
and also in vivo
106,107
. Thus, the accumulation 
of CL oxidation products in mitochondria of apoptotic cells has been found to be 
essential for the release of pro-apoptotic factors into the cytosol
103,108
. It was recently 
described that an integration of mono-unsaturated oleic acid into mitochondrial CL in 
mouse embryonic cells, led to the desensitization of apoptosis via suppression of CL 
54 
 
oxidation
103
.  Furthermore, the inhibition of long chain acyl-CoA synthase reinstated 
polyunsaturation of CL and sensitivity to apoptosis 
103
.  
Several studies have suggested a closed relationship between mitochondrial function 
and lipid composition. PC and PE are the most abundant phospholipids. Each class of 
phospholipid presents a unique molecular profile which independently of fatty acid 
composition modulates membrane structure
109
. Our results demonstrated lower levels of 
PC in P19 cells with forced oxidative metabolism which has been described during the 
differentiation of carcinoma embryonic cell line
102
. The increase of OXPHOS activity 
present in P19 cells growing in galactose-modified medium and consequent increased 
expression of some components of mitochondrial respiratory complexes, as complex II 
and IV subunits
79 
may result in a recruitment of several proteins to mitochondria. That 
protein translocation probably cause of transfer of PC between subcellular 
compartments and interaction with proteins. Thus, a loss of PC levels was detectable, as 
previously described during the differentiation of P19 cells into cardomiocytes
111
 and in 
a breast cancer cell line
112
.
 
 Differences in PE levels were also observed in P19 cells. PE 
is known to increase activity of cytochrome c oxidase, oxygen consumption and also the 
mitochondrial membrane potential
113
.  In fact, we observed in P19 differentiated cells 
growing in glucose media increased mitochondrial membrane potential as well as 
increased oxygen consumption
 
compared with their stemness counterparts
79
. Thus, 
increased of PE in Glu-dCCs may suggest its requirement for all of the processes 
associated with cell differentiation. However, when mitochondrial metabolism was 
forced the PE levels did not follow the tendency of Glu-dCCs, which may be related 
with some impairment in PE biosynthesis or loss of detectable PE in Gal-P19cells.  
Although significantly changes were not observed in the content of total CL during the 
differentiation of P19 cells with RA, CL synthesis and remodeling may be increased, 
with increased CL oxidation being observed. These findings suggest that P19 cells 
differentiation with RA increases the mitochondria activity and may allow the synthesis 
and translocation of mitochondrial enzymes for the processes of synthesis and 
remodeling of CL. The higher content of CLS in P19 dCCs seems to be a consequence 
of the higher mitochondrial activity and biogenesis promoted by the RA- induced cell 
differentiation
79
. Furthermore, we found that the content of taffazin increased in the 
cells with higher active mitochondrial metabolism. All these results support our 
hypothesis and previous findings about the strong mitochondrial remodeling induced 
during the differentiation of CSCs at both structural and functional levels
79
. As 
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previously observed, a stronger expression of  taffazin is associated with primary rectal 
cancer development and metastasis compared to distant or adjacent normal mucosa
114
. 
Furthermore, it is interesting notice that decreased the taffazin content is observed after 
anti-cancer therapy
114
. However our results showed higher content of taffazin in P19 
cells with higher mitochondrial activity, cells which are more susceptible to death. 
Thus, the remodeling of CL, by the presence of higher contents of taffazin, must be a 
reason for susceptibility in cells with active mitochondrial metabolism. Moreover, 
alterations in taffazin content may lead to different molecular species of CL observed 
during the differentiation of P19 EC cells as also described during differentiation of 
embryonic stem cells into cardiomyocytes, where the depletion of taffazin altered the 
pattern of molecular species of CL and also increased mitochondria with abnormal 
cristae
115
.  
The role of CL in mitochondrial activity and structure as well as in apoptosis was 
extensively investigated. It is known that the decline in mitochondrial respiratory 
functions leads to the accumulation of ROS. Under normal physiological conditions 
mitochondrial CL may protect cells from oxidative stress through the deacylation-
reacylation cycle
116
. However, CL is also a vulnerable target of ROS due to its 
unsaturated acyl chains and its close proximity to ROS generation sites
116
. It is also 
clear that during many cell death processes ROS and loss of CL are closely linked in a 
cycle of CL peroxidation. Recently evidences described that during P19 differentiation, 
higher content of mitochondrial superoxide anion is formed providing further evidence 
of mitochondrial remodeling during differentiation
79
. In this work we found an increase 
of peroxidized CL in differentiated cells (Glu-dCC and Gal-dCCs) in comparison to 
their stem counterparts which agree with the higher levels of ROS previously found in 
this type of P19 cells. The presence of peroxidized CL during apoptosis is usually 
described
107,130
 since this state of CL leads to its dissociation to cytochrome c allowing 
its release form mitochondria triggering the subsequent apoptotic events
61
. Thus, the 
more susceptible to mitochondrial poisons observed in P19 differentiated cells
79
 may be 
correlated with the higher CL peroxidation.  
In this work, we also evaluated the susceptibility of the four types of P19 cells studied 
to the main pineal hormone melatonin which have showed effective protective actions 
against several pathologic states through the impact on CL peroxidation
96
. Besides 
being a natural and potent free radical scavenger
78,83
, melatonin is reported to inhibits 
CL peroxidation in mitochondria preventing mitochondrial permeability transition and 
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cytochrome c release
116
, and therefore, regulating apoptosis
117
. In this work, we 
demonstrated that melatonin was not effective in reducing cell proliferation in P19 cells 
grown in high glucose medium. Interestingly, only cells grown in galactose-(glucose-
free) and glutamine-containing media were susceptible to the indolamine. Resistance to 
therapy, a hallmark of CSCs, seems to be strongly linked with the metabolic profile. 
Thus, some tumor cells are unable to produce ATP through mitochondria establishing a 
mitochondrial apoptosis resistant profile
118
. This glycolytic metabolism is also 
characteristic of many normal stem cells
119
.  Moreover, melatonin induced a prooxidant 
effect increasing lipid peroxidation in the P19 cells with an active oxidative metabolism. 
Thus, this prooxidant effect of melatonin may be related to its ability in decreasing the 
proliferation rate of some types of cancer cells
97
. Our results suggest that melatonin 
exerts its antiproliferative actions only in those cells which rely predominantly on 
oxidative phosphorylation for ATP synthesis by an action mediated by an increase in 
ROS production.  
A resistant profile of P19 Glu-CSCs against DCA, an anticancer drug that reverses the 
abnormal metabolism of cancer cells by shifting it from glycolysis to glucose oxidation 
was recently described
79
. In fact, just RA-induced P19 differentiated cells are 
susceptible to the effects of DCA, and its effects were higher with the increased of DCA 
concentration
79
. Thus, here we tested if the combination of melatonin with DCA could 
decrease the proliferation rate of P19 CSCs. In fact, we confirmed that the combined 
treatment decreases cell viability in all types of P19 cells (Appendix 3). Moreover, Glu-
CSCs resistant to the treatment with melatonin and DCA separately became susceptible 
when applied the combined treatment. After these evidences, we wanted to verify if the 
effect of the combined treatment was a consequence of higher CL peroxidation. We 
observed less peroxidized CL in RA differentiated cells treated with melatonin. In 
addition, the same effect was observed with the conjugated treatment. Hence, we may 
conclude that melatonin is able to prevent CL peroxidation in P19 differentiated cells as 
previously described
96
, and that the peroxidation of CL may not be the mechanism 
through which melatonin inhibits proliferation of both types of P19 cells with active 
mitochondrial metabolism (Gal-CSCs and Gal-dCCs). Taking into account all our 
results in the P19 cell line, we can infer that melatonin probably induces its cytotoxic 
effect via the inhibition of mitochondrial metabolism as also described in other types of 
tumor cells
120
. P19 Glu-CSCs present a strong resistant phenotype which seems to be 
extremely linked with their glycolytic metabolism. In fact, our group previously found 
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that only P19 cells with an active mitochondrial metabolism are susceptible to the 
anticancer agent DCA
8
. Furthermore, our results suggest that melatonin exert its 
cytotoxic effects also in P19 cells with an active oxidative metabolism, triggering a type 
of mitochondrial cell death which is caspases independent and which may involve the 
AIF. A similar pathway of melatonin-induced apoptosis was also observed in other 
types of cancer cells like MCF-7
121
. Therefore, mitochondrial activity, function and 
differentiation strongly impact the antitumoral hability of melatonin which involves, 
among others, the activation of intrinsic apoptotic pathways, at least in P19 embryonal 
carcinoma cells and in other types of cancer cells
120
.  It is known that AIF controls 
programmed cell death during early morphogenesis and that genetic inactivation of AIF 
renders embryonic stem cells resistant to cell death
122
. Thus, the mechanism of caspase-
independent cell death and the stimulation of mitochondrial metabolism constitute 
promissory strategies when targeting resistant cancer cells with an embryonic signature 
like P19 CSCs. In this context, these results support the possible use of melatonin-based 
treatments in limiting CSCs growth.
 
Hence, CL undergoes an intense remodeling during P19 CSCs differentiation that 
probably contributes in turning these cells susceptible to mitochondrial-targeted 
antitumor agents, while possibly participating in metabolic remodeling. 
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Cardiolipin is emerging as an important factor in the regulation of several mitochondrial 
processes, including respiratory chain complexes activity, inner membrane 
supermolecular assembly, anion carrier activity, binding of cytochrome c and 
functioning of other multiple mitochondrial inner membrane enzymes. Cardiolipin is 
also emerging as an important player in the control of mitochondrial apoptosis.  
In this thesis we can conclude that: 
 
 Cardiolipin remodeling accompanies the metabolic transformation towards a 
more oxidative metabolism that occurs during the differentiation of P19 CSCs. 
 The differentiation of P19 CSCs also induces the peroxidation of cardiolipin. 
The incorporation of oleic acid into cardiolipin from P19 CSCs allows us to 
conclude that P19 CSCs present a lower amount of non-oxidized cardiolipin. 
 Melatonin is only effective in reducing proliferation of P19 cells with higher 
oxidative metabolism.  Furthermore, melatonin is able to prevent cardiolipin 
peroxidation only in the P19 cells with more peroxidized cardiolipin (dCCs). In 
P19 CSCs, melatonin induces cardiolipin peroxidation. However, this 
mechanism is not the main contributor for melatonin antiproliferative actions in 
this cellular model.  
 The cytotoxic effects of melatonin in these cells with active oxidative 
metabolism could be mediated by triggering a type of mitochondrial cell death 
which may be mediated by AIF.  
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Regarding all the results present in this work and given the critical importance to 
cardiolipin, a mitochondrial phospholipid, as having a high potential in the regulation of 
the apoptosis, we plan to investigate the mechanisms underlying CL regulation in 
differentiation of P19 ESC. Moreover, we plan in assessing how CL will bring value 
information about the chemotherapies resistance in this CSCs model.  
To further explore these mechanisms, we propose silencing CLS in these cells. 
First, we will confirm the effects of CLS silencing in P19 differentiation, trough the 
expression of differentiation markers such as Musashi, betaIII-tubulin and TROMA1. 
Then, we plan verify the CL content and peroxidation using the TLC and NAO probe 
respectively. After this we will check the phenotype resulting from CLS silencing on 
differentiation through the oxygen consumption and the transmembrane potential in P19 
cells in different stages of differentiation 
Regarding the role of CL in resistance to chemotherapeutics, we proposed evaluate CLS 
silencing effects in cell susceptibility to chemotherapies. In addition to the compounds 
already used in this work (DCA and melatonin) we plan to use doxorubicin and 
etoposidium described as effective antitumor agents
123,124,125
.  Furthermore, we plan to 
identify the apoptotic events associated with the treatment with these four agents, 
measuring the release of cytochrome c from mitochondria to the cytoplasmatic region, 
measure caspases 3 and 9 activities and finally induction of the mitochondrial 
permeability transition.  
  Finally, to consolidate the results obtained in this work, we also propose 
evaluate the expression of CLS and taffazin in cells treated with DCA and melatonin in 
concentrations previously administrated, and thus verify whether these two agents affect 
the synthesis and remodeling of CL. 
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 Effect of the combined treatment with melatonin and dichloroacetate (DCA) on cell 
viability of P19 embryonal carcinoma stem (CSCs) and differentiated (dCCs) cells, grown in 
glucose (Glu) and galatose (Gal) media. The sulforhodamine B (SRB) assay shows a cytotoxic 
effect in Glu-CSCs after 72 hours of the combined treatment with 1mM melatonin and 10 mM 
dichloroacetate. Data represent the average percentage of SRB absorbance with respective time 
0 ± SEM from at least four independent experiments. Data are optical density (O.D.) expressed 
as percentage of control ± SEM from three separate immunoblots. * p<0.05; ** p<0.01; *** 
p<0.001 vs.control. 
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